# DESCRIPTION

- introduce heart failure problem
- motivate need for cardiovascular progenitors
- summarize limitations of current stem cell sources
- highlight potential of embryonic stem cells
- describe need for efficient differentiation method
- introduce invention's objective
- outline method for preparing cardiovascular progenitors
- describe preferred embodiments of the invention
- describe cell culture method
- motivate platelet lysate use
- detail platelet lysate preparation
- outline cardiac progenitor cell differentiation
- describe cell separation and kit composition

## MATERIALS AND METHODS FOR EXAMPLES 1-3

- list materials and equipment

### Equipment

- list equipment

### Culture of Primate ES Cells

- describe culture of primate ES cells

### Protocol to Direct the Fate and to Differentiate Primate ES Cells Toward a Cardiac Lineage

- describe protocol to direct fate and differentiate primate ES cells

### Generation and Selection of Cardiovascular Progenitors

- describe generation and selection of cardiovascular progenitors

### Culture of Primate ES cells in a Clinical Grade Medium

- describe culture of primate ES cells in clinical grade medium

## BOX 1: Cell Passaging

- describe cell passaging

## BOX 2: RT-PCR and Real Time Quantitative PCR

- describe RT-PCR and real time quantitative PCR

## Example 4

### A) Materials and Methods

- describe materials and methods

### B) Culture and Cardiac Commitment of Human Embryonic Stem Cells

- describe culture and cardiac commitment of human embryonic stem cells

### C) Myocardial Infarction Model

- describe myocardial infarction model

### D) Rats Randomization and Myocardial Cell Injection

- describe rats randomization and myocardial cell injection

### E) Histopathology

- describe histopathology

### F) Results

- describe results

## Example 5

### Generation of CD15+ Cardiovascular Progenitors from Human iPS Cell Line

- generate CD15+ cardiovascular progenitors

## Discussion

- demonstrate cardiomyocyte differentiation without teratoma formation
- discuss BMP2 as a cardiogenic factor
- discuss safety and efficacy of cardiac-committed HES cells
- discuss limitations and future directions of HES cell-derived cardiomyocytes

